OP23A CONSENSUS WORKSHOP TO DEVELOP RISK-BASED SELECTION CRITERIA FOR THE NEXT SIOP TRIAL OF “SIGHT-SAVING THERAPY” FOR CHILDREN WITH NF1-ASSOCIATED OPTIC PATHWAY GLIOMA (NF1-OPG) | Zendy

AI Assistant Blog Pricing

OP23A CONSENSUS WORKSHOP TO DEVELOP RISK-BASED SELECTION CRITERIA FOR THE NEXT SIOP TRIAL OF “SIGHT-SAVING THERAPY” FOR CHILDREN WITH NF1-ASSOCIATED OPTIC PATHWAY GLIOMA (NF1-OPG)

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.